Table 2 Clinical characteristics of CSR OMG and non-CSR OMG
From: Thymectomy in ocular myasthenia gravis—prognosis and risk factors analysis
Overall (52) | CSR OMG (16) | Non-CSR OMG (36) | p value | |
|---|---|---|---|---|
Gender, n (%) | 0.282 | |||
Male | 22 (42.3%) | 5 (31.3%) | 17 (47.2%) | |
Female | 30 (57.7%) | 11 (68.8%) | 19 (52.8%) | |
Onset age (years), mean ± SD | 54.7 ± 13.5 | 48.3 ± 13.7 | 57.5 ± 12.6 | 0.022* |
Onset age (years), n (%) | 0.016* | |||
≤ 60 | 33 (63.5%) | 14 (87.5%) | 19 (52.8%) | |
> 60 | 19 (36.5%) | 2 (12.5%) | 17 (47.2%) | |
Ptosis, n (%) | 0.765c | |||
Left | 18 (34.6%) | 6 (37.5%) | 12 (33.3%) | |
Right | 14 (26.9%) | 5 (31.3%) | 9 (25.0%) | |
Bilateral | 20 (38.5%) | 5 (31.3%) | 15 (41.7%) | |
Diplopia ( +), n (%) | 21 (40.4%) | 9 (56.3%) | 12 (33.3%) | 0.120 |
Anti-AchR Ab ( +), n (%) | 34 (65.4%) | 7 (43.8%) | 27 (75.0%) | 0.029* |
RNS ( +), n (%) | 23 (44.2%) | 4 (25.0%) | 19 (52.8%) | 0.063 |
Disease duration before surgery (weeks), mean ± SD | 19.4 ± 46.6 | 8.6 ± 9.9 | 24.1 ± 55.2 | 0.111 |
Surgical approach, n (%) | 0.056c | |||
R/L-VATS | 22 (42.3%) | 10 (62.5%) | 12 (33.3%) | |
TS | 8 (15.4%) | 3 (18.8%) | 5 (13.9%) | |
Sub-xiphoid | 22 (42.3%) | 3 (18.8%) | 19 (52.8%) | |
Tumor location, n (%) | 0.488b | |||
Left | 19 (48.7%) | 4 (40.0%) | 15 (51.7%) | |
Right | 18 (46.2%) | 5 (50.0%) | 13 (44.8%) | |
L + Ra | 2 (5.1%) | 1 (10%) | 1 (3.4%) | |
Maximum diameter (cm) mean ± SD | 3.8 ± 1.6 | 3.6 ± 2.2 | 3.9 ± 1.4 | 0.592 |
Median size (cm) mean ± SD | 3.1 ± 1.3 | 3.0 ± 1.7 | 3.1 ± 1.1 | 0.739 |
Thymoma histotype + hyperplasia, n (%) | 0.330b | |||
Thymoma | ||||
AB | 9 (17.3%) | 1 (6.3%) | 8 (22.2%) | |
B1 | 4 (7.7%) | 2 (12.5%) | 2 (5.6%) | |
B2 | 18 (34.6%) | 4 (25.0%) | 14 (38.9%) | |
B3 | 8 (15.4%) | 3 (18.8%) | 5 (13.9%) | |
Hyperplasia | 13 (25.0%) | 6 (37.5%) | 7 (19.4%) | |
Thymoma Stage + hyperplasia, n (%) | 0.086b | |||
Thymoma | ||||
I | 9 (17.3%) | 5 (31.3%) | 4 (11.1%) | |
IIa | 12 (23.1%) | 1 (6.3%) | 11 (30.6%) | |
IIb | 12 (23.1%) | 2 (12.5%) | 10 (27.8%) | |
III | 6 (11.5%) | 2 (12.5%) | 4 (11.1%) | |
Hyperplasia | 13 (25.0%) | 6 (37.5%) | 7 (19.4%) | |
Hyperplasia: thymoma | 13:39 | 6:10 | 7:29 | 0.298 |
Hyperplasia + I: II + III | 22:30 | 11:5 | 11:25 | 0.010* |
NTOMG, n (%) | 0.592b | |||
Early-onset (age ≤ 50) | 7 (13.5%) | 4 (25%) | 3 (8.3%) | |
Late-onset (age > 50) | 6 (11.5%) | 2 (12.5%) | 4 (11.1%) | |
Post-operative prednisone ( +), n (%) | 18 (34.6%) | 5 (31.3%) | 13 (36.1%) | 0.734 |
Post-operative follow-up duration (months), mean ± SD | 60.5 ± 27.7 | 78.3 ± 28.6 | 58.3 ± 25.4 | 0.015* |